within Pharmacolibrary.Drugs.N_NervousSystem.N06A_Antidepressants.N06AX14_Tianeptine;

model Tianeptine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.99,
    Cl = 8.333333333333333e-07,
    adminDuration = 600,
    adminMass = 12.5 / 1000000,
    adminCount = 1,
    Vd = 0.0008,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.017333333333333333,
    Tlag = 15.0);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Tianeptine</td></tr><tr><td>ATC code:</td><td>N06AX14</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>12.5</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.8</td><td>L</td></tr>
    <tr><td>clearance:</td><td>3.0</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Tianeptine is an atypical antidepressant primarily used for the treatment of major depressive disorder. It has unique pharmacological properties, including enhancement of serotonin uptake, modulation of glutamatergic activity, and neuroprotective effects. Tianeptine is approved for use in several countries in Europe and Asia, though it is not FDA-approved in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for healthy adult volunteers following a single oral dose; data primarily from published studies.</p><h4>References</h4><ol><li><p>Grasela, TH, et al., &amp; Jochemsen, R (1993). Development of a population pharmacokinetic database for tianeptine. <i>European journal of clinical pharmacology</i> 45(2) 173–179. DOI:<a href=\"https://doi.org/10.1007/BF00315502\">10.1007/BF00315502</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8223841/\">https://pubmed.ncbi.nlm.nih.gov/8223841</a></p></li><li><p>Royer, RJ, et al., &amp; Kamoun, A (1988). Pharmacokinetic and metabolic parameters of tianeptine in healthy volunteers and in populations with risk factors. <i>Clinical neuropharmacology</i> 11 Suppl 2 S90–S96. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3180120/\">https://pubmed.ncbi.nlm.nih.gov/3180120</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N06AX14 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Tianeptine;
